Adage Capital Partners
AGRX

Adage Capital Partners’s Agile Therapeutics AGRX Stock Holding History

Adage Capital Partners’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-850
Closed -$9.69M – 755
2016
Q4 		$9.69M Hold
850
– – 0.03% 534
2016
Q3 		$11.9M Hold
850
– – 0.03% 487
2016
Q2 		$12.9M Hold
850
– – 0.04% 464
2016
Q1 		$10.6M Buy
850
+150
+21% +$1.94M 0.03% 505
2015
Q4 		$13.7M Buy
700
+2
+0.3% +$31.6K 0.04% 465
2015
Q3 		$9.41M Hold
698
– – 0.03% 544
2015
Q2 		$12M Hold
698
– – 0.03% 520
2015
Q1 		$12.9M Buy
698
+98
+16% +$1.72M 0.03% 513
2014
Q4 		$7.37M Hold
600
– – 0.02% 579
2014
Q3 		$8.76M Hold
600
– – 0.02% 552
2014
Q2 		$10.5M Buy
+600
New +$8.68M 0.03% 520

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Adage Capital Partners's AGRX Position: Q1 2017 in Review

Adage Capital Partners sold out of Agile Therapeutics (AGRX) in Q1 2017, closing a stake of 850 shares — an estimated $9.69M sold.

Adage Capital Partners first reported a position in AGRX in Q2 2014 and held it in 11 quarters. The position peaked at $13.7M in Q4 2015. 48 funds tracked by Wall St. Rank hold AGRX as of Q1 2017.

  • Adage Capital Partners reported no remaining Agile Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Adage Capital Partners sold 850 Agile Therapeutics shares in Q1 2017, an estimated $9.69M.
  • Adage Capital Partners first reported a position in Agile Therapeutics in Q2 2014 and held it in 11 quarters.
  • Adage Capital Partners's Agile Therapeutics position peaked at $13.7M in Q4 2015.
  • 48 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2017.

Based on Adage Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.